Jean-Charles Nault1, Frédéric Pigneur2, Anaïs Charles Nelson3, Charlotte Costentin1, Lambros Tselikas2, Sandrine Katsahian3, Guoqing Diao4, Alexis Laurent5, Ariane Mallat6, Christophe Duvoux6, Alain Luciani7, Thomas Decaens8. 1. APHP, Groupe Henri Mondor Albert Chenevier, Liver Unit, Henri Mondor Hospital, Créteil, France. 2. APHP, Groupe Henri Mondor Albert Chenevier, Department of Radiology, Henri Mondor Hospital, Créteil, France. 3. APHP, Groupe Hôpital Européen Georges Pompidou, Department of Clinical Research, Paris, France; INSERM, UMRS 1138, Team 22, Department of Research of Les Cordeliers, Paris, France; University Paris 5 René Descartes, Paris, France. 4. Department of Statistics, George Mason University, Fairfax, VA, USA. 5. APHP, Groupe Henri Mondor Albert Chenevier, Department of Hepatobiliary Surgery, Henri Mondor Hospital, Créteil, France; University Paris Est Créteil, Créteil, France; INSERM U955, Team 18, Créteil, France. 6. APHP, Groupe Henri Mondor Albert Chenevier, Liver Unit, Henri Mondor Hospital, Créteil, France; University Paris Est Créteil, Créteil, France; INSERM U955, Team 18, Créteil, France. 7. APHP, Groupe Henri Mondor Albert Chenevier, Department of Radiology, Henri Mondor Hospital, Créteil, France; University Paris Est Créteil, Créteil, France; INSERM U955, Team 18, Créteil, France. 8. APHP, Groupe Henri Mondor Albert Chenevier, Liver Unit, Henri Mondor Hospital, Créteil, France; University Paris Est Créteil, Créteil, France; INSERM U955, Team 18, Créteil, France. Electronic address: tdecaens@chu-grenoble.fr.
Abstract
BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS: Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with drug toxicity, radiological response, and overall survival. RESULTS: 52 patients were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of α-fetoprotein of 29,554±85,654 ng/mL, with a median overall survival of 10.5 months. Sarcopenia was associated with a greater rate of hand-foot syndrome (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of hand-foot syndrome and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of hand-foot syndrome (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma.
BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS:Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with drug toxicity, radiological response, and overall survival. RESULTS: 52 patients were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of α-fetoprotein of 29,554±85,654 ng/mL, with a median overall survival of 10.5 months. Sarcopenia was associated with a greater rate of hand-foot syndrome (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of hand-foot syndrome and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of hand-foot syndrome (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma.
Authors: Tianying Zheng; Hanyu Jiang; Yi Wei; Zixing Huang; Jie Chen; Ting Duan; Bin Song Journal: Chin J Cancer Res Date: 2018-06 Impact factor: 5.087
Authors: Tim A Labeur; Jeroen L A van Vugt; David W G Ten Cate; R Bart Takkenberg; Jan N M IJzermans; Bas Groot Koerkamp; Robert A de Man; Otto M van Delden; Ferry A L M Eskens; Heinz-Josef Klümpen Journal: Liver Cancer Date: 2018-11-02 Impact factor: 11.740